Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases Earnings Results, Misses Expectations By $0.03 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03), Zacks reports. Alnylam Pharmaceuticals updated its FY 2025 guidance to EPS.

Alnylam Pharmaceuticals Price Performance

ALNY traded down $8.44 during trading on Monday, reaching $256.45. The stock had a trading volume of 805,993 shares, compared to its average volume of 695,622. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The business has a 50-day moving average of $254.03 and a 200-day moving average of $263.53. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39. The stock has a market cap of $33.08 billion, a PE ratio of -97.88 and a beta of 0.35.

Analysts Set New Price Targets

ALNY has been the topic of a number of recent research reports. Barclays raised their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a report on Friday, November 1st. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. TD Cowen increased their target price on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a "buy" rating in a report on Monday, October 21st. Scotiabank cut their price target on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating on the stock in a report on Friday. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $299.43.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares in the company, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now directly owns 78,880 shares in the company, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 73,964 shares of company stock worth $20,622,925. 1.50% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.